PEDIATRICS Vol. 55 No. 3 March 1975, pp. 342-347
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, J. A.
Right arrow Articles by Koplan, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, J. A.
Right arrow Articles by Koplan, J. P.

Smallpox Vaccination Reactions, Prophylaxis, and Therapy of Complications

Joel A. Goldstein M.D.1, John M. Neff M.D.1, J. Michael Lane M.D.1, and Jeffrey P. Koplan M.D.1

1 Bureaus of Smallpox Eradication and State and Community Services, Center for Disease Control, Atlanta, Georgia, and The Johns Hopkins School of Medicine, Baltimore Maryland

Smallpox vaccination in the United States is a routine public health measure which has been under intensive review during the last decade. The most frequently occurring adverse reactions to vaccination are benign and require little or no systemic therapy. These reactions include accidental infection, erythematous and urticarial rash, and generalized vaccinia. Chickenpox occurring concurrently with vaccination presents no problem unless vaccinia has widely superinfected the chickenpox lesions. There is no risk to the pregnant woman who is vaccinated, but there is a slight risk that the fetus will develop fetal vaccinia. The vaccinia does not cause congenital malformations. Vaccinia hyperimmune globulin (VIG) in prophylactic dosage may be given to a pregnant woman who is traveling to a smallpox infected or endemic area in order to prevent fetal vaccinia.

Vaccinia necrosum and eczema vaccinatum require vigorous systemic therapy with VIG, and often thiosemicarbazone. Post-vaccinial encephalitis, while frequently serious, has not been shown to be ameliorated by VIG therapy, although there are data which suggest VIG has some value in prophylaxis for encephalitis. Prophylaxis, prompt recognition, and proper therapy may reduce the fatality rates of these complications.

Revaccination of patients who have suffered a complication is a frequent clinical problem. Revaccination of an individual who has had post-vaccinial encephalitis or vaccinia necrosum is contraindicated unless the risk of contracting smallpox outweighs the risk of the above two diseases. Revaccination of children who have had eczema vaccinatum is not contraindicated. Revaccination of children with a history of accidental infection or erythematous or urticarial rash presents no known or theoretically increased risk.

Accepted on June 17, 1974




This article has been cited by other articles:


Home page
 Journal of the American Dental AssociationHome page
J. Rinaggio and M. Glick
The smallpox vaccine: An update for oral health care professionals
J Am Dent Assoc, April 1, 2006; 137(4): 452 - 460.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. D. Shearer, L. Siemann, M. Gerkovich, and R. V. House
Biological Activity of an Intravenous Preparation of Human Vaccinia Immune Globulin in Mouse Models of Vaccinia Virus Infection
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2634 - 2641.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
R. D. Semba
The Ocular Complications of Smallpox and Smallpox Immunization--Reply
Arch Ophthalmol, September 1, 2004; 122(9): 1407 - 1408.
[Full Text] [PDF]

Home page
 J. Virol.Home page
N. Benning and D. E. Hassett
Vaccinia Virus Infection during Murine Pregnancy: a New Pathogenesis Model for Vaccinia Fetalis
J. Virol., March 15, 2004; 78(6): 3133 - 3139.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
A. Cosma, S. Buhler, R. Nagaraj, C. Staib, A.-L. Hammarin, B. Wahren, F. D. Goebel, V. Erfle, and G. Sutter
Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia Virus
Clin. Vaccine Immunol., March 1, 2004; 11(2): 406 - 410.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. D. Kelly, C. Egan, S. W. Davis, W. A. Samsonoff, K. A. Musser, P. Drabkin, J. R. Miller, J. Taylor, and N. M. Cirino
Laboratory Confirmation of Generalized Vaccinia following Smallpox Vaccination
J. Clin. Microbiol., March 1, 2004; 42(3): 1373 - 1375.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
A. L. Naleway, E. A. Belongia, R. T. Greenlee, B. A. Kieke Jr, R. T. Chen, and D. K. Shay
Eczematous Skin Disease and Recall of Past Diagnoses: Implications for Smallpox Vaccination
Ann Intern Med, July 1, 2003; 139(1): 1 - 7.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. Miravalle and K. L. Roos
Encephalitis Complicating Smallpox Vaccination
Arch Neurol, July 1, 2003; 60(7): 925 - 928.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
T. R. Talbot, H. K. Bredenberg, M. Smith, B. J. LaFleur, A. Boyd, and K. M. Edwards
Focal and Generalized Folliculitis Following Smallpox Vaccination Among Vaccinia-Naive Recipients
JAMA, June 25, 2003; 289(24): 3290 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
R. D. Semba
The Ocular Complications of Smallpox and Smallpox Immunization
Arch Ophthalmol, May 1, 2003; 121(5): 715 - 719.
[Abstract] [Full Text] [PDF]

Home page
 Biol Res NursHome page
C. M. Constantin, A. M. Martinelli, E. A. Bonney, and O. L. Strickland
Smallpox: An Update for Nurses
Biol Res Nurs, April 1, 2003; 4(4): 282 - 294.
[Abstract] [PDF]

Home page
 Clin Med ResHome page
E. A. Belongia and A. L. Naleway
Smallpox Vaccine: The Good, the Bad, and the Ugly
Clin. Med. Res., April 1, 2003; 1(2): 87 - 92.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. M. Lane and J. Goldstein
Evaluation of 21st-Century Risks of Smallpox Vaccination and Policy Options
Ann Intern Med, March 18, 2003; 138(6): 488 - 493.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. A. Bozzette, R. Boer, V. Bhatnagar, J. L. Brower, E. B. Keeler, S. C. Morton, and M. A. Stoto
A Model for a Smallpox-Vaccination Policy
N. Engl. J. Med., January 30, 2003; 348(5): 416 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
V. R. Suarez and G. D. V. Hankins
Smallpox and Pregnancy: From Eradicated Disease to Bioterrorist Threat
Obstet. Gynecol., July 1, 2002; 100(1): 87 - 93.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. A. Henderson, T. V. Inglesby, J. G. Bartlett, M. S. Ascher, E. Eitzen, P. B. Jahrling, J. Hauer, M. Layton, J. McDade, M. T. Osterholm, et al.
Smallpox as a Biological Weapon: Medical and Public Health Management
JAMA, June 9, 1999; 281(22): 2127 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Public HealthHome page
S. S. Ellenberg, M. A. Foulkes, K. Midthun, and K. L. Goldenthal
Evaluating the Safety of New Vaccines: Summary of a Workshop
Am J Public Health, May 1, 2005; 95(5): 800 - 807.
[Abstract] [Full Text] [PDF]